The Benefits of GLP-1 Receptors in Cardiovascular Diseases
Only four saw a slight regain, with the largest increase being 8 lbs
On semaglutide, people lost about 15% of their body weight over a little more than a year (Wilding, New England Journal of Medicine, 2021), and tirzepatide, what I take, runs higher than that
Disclosures: Teiji Kuzuya: Chugai Pharmaceutical Co: Speaking and Teaching, Eisai: Speaking and Teaching, Eli Lilly Japan: Speaking and Teaching, AstraZeneca: Speaking and Teaching, Naoto Kawabe: Nothing to Disclose, Yoshiki Hirooka: Nothing to Disclose 1822 A COMPARATIVE VALIDATION OF CLINICAL PREDICTION SCORES FOR HEPATOCELLULAR CARCINOMA IN STEATOTIC LIVER DISEASE WITHOUT CIRRHOSIS Catherine Mezzacappa 1 Janet Tate 1 Tamar Taddei 1 Amy Justice 1 , 1 Yale University Background: Many clinical risk scores to predict hepatocellular carcinoma (HCC) have been assessed in cohorts without known cirrhosis or viral hepatitis, whose HCC risk is driven by steatotic liver disease (SLD)
.jpg)
